Clinical trials: Bevacizumab
Rectal Cancer
Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer
This study includes patients affected by advanced and resectable rectal adenocarcinoma. It provides an induction chemotherapy with FOLFOXIRI regimen plus Bevacizumab followed by Chemoradiotherapy plus Bevacizumab.
- Trial name
- TRUST (NCT03085992)
- Testing
- FOLFOXIRI plus Bevacizumab, Chemoradiotherapy plus Bevacizumab
- Where
- 4 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Cervical Cancer, Endometrial Cancer
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
This research study is evaluating a drug called avastin in combination with standard radiation as a possible treatment for treatment for recurrent pelvic-confined gynecological cancer (i.e.
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer
- Trial name
- NCT00545792
- Testing
- Avastin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
In this research study, we aim to evaluate the feasibility, toxicity and efficacy of early multimodality systemic therapy (a combination of docetaxe, bevacizumab, and androgen deprivation therapy(ADT) in men with biochemical…
- Trial name
- NCT00658697
- Testing
- Docetaxel, Bevacizumab, ADT
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dana-Farber Cancer Institute
Lung, Carcinoma
Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer
Epidermal growth factor receptor (EGFR) tyrosine kinase is one of most popular target molecules in the field of anticancer drug research.
- Trial name
- NCT02139579
- Testing
- Bevacizumab
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer
This study will assess the efficacy and safety of two different neoadjuvant treatment approaches including bevacizumab in newly diagnosed participants with high risk locally advanced rectal cancer.
- Trial name
- INOVA (NCT00865189)
- Testing
- Bevacizumab, Oxaliplatin, Folinic Acid
- Where
- 40 sites in France
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer
This is a multicenter, Phase III, randomized, active-controlled trial to evaluate the efficacy and safety of rhuMAb VEGF (Avastin) added to the standard first-line chemotherapy used to treat metastatic colorectal cancer.
- Trial name
- NCT00109070
- Testing
- Avastin (bevacizumab)
- Sponsor
- Genentech, Inc.
Colorectal Carcinoma, Liver Metastases
FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma
This pilot study will evaluate the safety and effectiveness of chemo-radiotherapy comprising a regimen of FOLFOX6 chemotherapy plus SIR-Spheres yttrium-90 microspheres (chemo-radiotherapy, also known as "chemo-SIRT"), in…
- Trial name
- FAST (NCT00735241)
- Testing
- SIR-Spheres microspheres, FOLFOX6 cycles 1-3, FOLFOX6 cycles 4 onwards
- Where
- 3 sites in United States
- Sponsor
- Sirtex Medical
Unresectable Hepatocellular Carcinoma
A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization
This is a multicenter, retrospective, observational cohort study to describe the effectiveness and safety of Atezo+Bev plus Transarterial Chemoembolization (TACE) among adult patients with unresectable hepatocellular carcinoma…
- Trial name
- NCT06503250
- Testing
- Atezolizumab, Bevacizumab, Transarterial Chemoembolization
- Where
- 5 sites in China
- Volunteers
- 113 people
- Sponsor
- Hoffmann-La Roche
Glioblastoma
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.
- Trial name
- NCT03743662
- Testing
- Re-irradiation (RT), Bevacizumab, Nivolumab
- Where
- 11 sites in United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioma, Malignant
ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab
This is a treatment clinical trial to assess the efficacy of ERC1671 in combination with bevacizumab and pembrolizumab in patients with GBM that has progressed following treatment with radiation and temozolomide.
- Trial name
- NCT05366062
- Testing
- ERC1671, GM-CSF, Cyclophosphamide
- Where
- Thailand
- Volunteers
- 28 people
- Sponsor
- Epitopoietic Research Corporation
Lung Cancer
Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab
RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment for non-small cell lung cancer may help doctors predict how patients will respond to treatment.
- Trial name
- NCT00898417
- Testing
- bevacizumab, carboplatin, paclitaxel
- Volunteers
- 90 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
This randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b to see how well it works compared to octreotide acetate and bevacizumab in treating patients with high-risk neuroendocrine tumors that…
- Conditions
- Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor
- Trial name
- NCT00569127
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate
- Where
- 493 sites in United States
- Volunteers
- 427 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Angiogenesis
Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma
This retrospective non - interventional patient chart review will be utilizing real world clinical data from patients treated for rGBM at the University Regensburg Medical center either with or without bevacizumab.
- Trial name
- NCT04974983
- Testing
- Observation of neurological deficits
- Where
- Germany
- Volunteers
- 203 people
- Sponsor
- University Hospital Regensburg
Sarcoma, Soft Tissue Sarcoma
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
The purpose of this study is to test the combination of the chemotherapy drugs Gemcitabine, bevacizumab, and docetaxel with valproic acid to treat patients with metastatic sarcoma.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Locally Advanced Sarcoma, Unresectable Sarcoma
- Trial name
- NCT01106872
- Testing
- Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Mohammed M Milhem
Ovarian Neoplasms
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) in combination with bevacizumab works in treating platinum-sensitive ovarian cancer compared to standard treatments by checking whether it makes…
- Trial name
- NCT07684612
- Testing
- Mocertatug rezetecan (Mo-Rez), Carboplatin, Paclitaxel
- Where
- 9 sites in Australia, Canada and 2 more
- Volunteers
- 690 people
- Sponsor
- GlaxoSmithKline
Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
The goal of this clinical trial is to test the safety of the trifluridine/tipiracil as replacement of fluoropyrimidines based chemotherapy as first line metastatic colorectal or gastroesophageal cancer regimens in patients with…
- Conditions
- Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency
- Trial name
- TRIFLUOX-DP (NCT06245356)
- Testing
- Lonsurf, Oxaliplatin, Panitumumab
- Where
- 21 sites in France
- Volunteers
- 73 people
- Sponsor
- UNICANCER
Diabetic Macular Edema
Intravitreal Triamcinolone Acetonide Versus Intravitreal Bevacizumab for Refractory Diabetic Macular Edema (IBEME Study)
Intravitreal triamcinolone has been effective for central macular thickness reduction and concomitant visual acuity improvement in patients with diabetic macular edema (DME).
- Trial name
- IBEME (NCT00468351)
- Testing
- Intravitreal Injection of 1,5 mg of bevacizumab, Intravitreal injection of 4 mg of Triamcinolone acetonide
- Where
- Brazil
- Sponsor
- University of Sao Paulo
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent).
- Conditions
- Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT05231122
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Roswell Park Cancer Institute
Glioblastoma, Gliosarcoma
Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas
Primary objective- To determine efficacy of Avastin, 10 mg/kg every other week, in combination with standard 5-day temozolomide in terms of response rate.
- Trial name
- NCT00612339
- Testing
- Avastin and Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Duke University
Hepatocellular Carcinoma
The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma
Hepatocellular carcinoma is one of the most common solid malignant tumors. The prognosis of unresectable hepatocellular carcinoma is very poor.
- Trial name
- NCT05760430
- Testing
- PVE+cTACE+Camrelizumab+Apatinib, cTACE+Atirizumab+Bevacizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine